Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
Analysts See $-0.58 EPS for Nektar Therapeutics (NKTR) - Money Making Articles Hot Stuff

Analysts See $-0.58 EPS for Nektar Therapeutics (NKTR)

October 13, 2018 - By Vivian Park

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.13 in Q2 2018. Its down 0.30, from 1.43 in 2018Q1. It worsened, as 54 investors sold Nektar Therapeutics shares while 100 reduced holdings. 82 funds opened positions while 92 raised stakes. 157.21 million shares or 2.48% more from 153.40 million shares in 2018Q1 were reported.
Da Davidson has 0% invested in Nektar Therapeutics (NASDAQ:NKTR) for 4,600 shares. Fairfield Bush & has 0.17% invested in Nektar Therapeutics (NASDAQ:NKTR) for 12,000 shares. Cibc Asset Management accumulated 13,915 shares or 0% of the stock. The New York-based Bancshares Of Mellon has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). Hillhouse Capital Mngmt Limited holds 0.09% or 107,471 shares in its portfolio. Global X Management Limited Liability Company holds 0.01% or 6,462 shares in its portfolio. Invesco holds 2.12M shares. Daiwa Grp Inc holds 6,544 shares. Toronto Dominion National Bank invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Franklin has invested 0.02% in Nektar Therapeutics (NASDAQ:NKTR). The New York-based Tiaa Cref Inv Mngmt Lc has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR). Primecap Management Ca holds 0.76% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR) for 20.90M shares. Parametric Port owns 277,274 shares. Vident Inv Advisory Limited Liability Com has 0.1% invested in Nektar Therapeutics (NASDAQ:NKTR) for 52,994 shares. Guardian Life Of America reported 0% stake.

Since April 16, 2018, it had 1 buy, and 24 selling transactions for $39.19 million activity. The insider Lingnau Lutz sold 9,000 shares worth $512,820. CHESS ROBERT had sold 4,500 shares worth $255,645 on Wednesday, September 19. The insider Hora Maninder sold $338,563. On Monday, June 4 GREER R SCOTT sold $602,786 worth of Nektar Therapeutics (NASDAQ:NKTR) or 10,000 shares. $286,445 worth of stock was sold by Doberstein Stephen K on Wednesday, May 16. The insider Nicholson John sold $410,029.

Analysts expect Nektar Therapeutics (NASDAQ:NKTR) to report $-0.58 EPS on November, 6.They anticipate $0.95 EPS change or 256.76 % from last quarter’s $0.37 EPS. After having $5.33 EPS previously, Nektar Therapeutics’s analysts see -110.88 % EPS growth. The stock increased 2.11% or $1.01 during the last trading session, reaching $48.91. About 1.85M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 187.03% since October 14, 2017 and is uptrending. It has outperformed by 171.41% the S&P500.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 6 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Nektar Therapeutics had 7 analyst reports since April 20, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, June 4 by Cowen & Co. The stock has “Buy” rating by Canaccord Genuity on Tuesday, June 5. The firm has “Buy” rating given on Friday, May 11 by Canaccord Genuity. H.C. Wainwright downgraded Nektar Therapeutics (NASDAQ:NKTR) on Monday, June 11 to “Neutral” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Overweight” rating given on Monday, June 4 by JP Morgan.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $8.44 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It has a 9.1 P/E ratio. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

More recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Nasdaq.com which released: “Did Bristol-Myers Squibb Make a Huge Mistake With Nektar?” on October 02, 2018. Also Seekingalpha.com published the news titled: “Pegging The Value Of NKTR-214 At Zero” on October 02, 2018. Seekingalpha.com‘s news article titled: “Refuting Nektar’s Apparent Response To Our Initial Report” with publication date: October 04, 2018 was also an interesting one.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:



Warning: mysqli_query(): (HY000/1030): Got error 28 from storage engine in /home/mmahotstuff3/public_html/wp-includes/wp-db.php on line 1924
>